ARR3 and age-related macular degeneration: Chronic administration of the combination may be a useful adjunct to the therapeutic benefit of AREDS in slowing the loss of photoreceptor cells and the progression of AMD to advanced disease by regulating retinal gene expression, and increasing rhodopsin, rod S-antigen, cone opsin and cone arrestin.